Development and validation of the economic assessment of glycemic control and long-term effects of diabetes (EAGLE) model

Diabetes Technology and Therapeutics

Volumn 8, Issue 2, 2006, Pages 219-236

  Mueller, Elvira ^a,f   Maxion Bergemann, Stefanie ^a   Gultyaev, Dmitry ^a   Walzer, Stefan ^a   Freemantle, Nick ^b   Mathieu, Chantal ^c   Bolinder, Bjorn ^d   Gerber, Robert ^e   Kvasz, Marion ^e   Bergemann, Rito ^a  

^a Analytica International ^*  (Germany)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d SANOFI   (France)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^f Outcomes Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN;

ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; COST OF ILLNESS; DEATH; DIABETIC FOOT; DIABETIC MICROANGIOPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; ECONOMIC ASSESSMENT OF GLYCEMIC CONTROL AND LONG TERM EFFECTS OF DIABETES MODEL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETINA MACULA EDEMA; RISK ASSESSMENT; SIMULATION; STATISTICAL MODEL; STROKE; VALIDATION PROCESS;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; MONTE CARLO METHOD;

EID: 33744943246     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2006.8.219     Document Type: Article

References (52)

1. Streufert S, Satish U, Barach P: Improving medical care: the use of simulation technology. Simul Gaming 2001;32:164-174.
2. Kuntz K, Weinstein M: Modelling in economic evaluation. In: Drummond M, McGuire A, eds. Economic Evaluation in Health Care-Merging Theory with Practice. Oxford: Oxford University Press, 2002:141-171.
3. Ramsey SD, McIntosh M, Etzioni R, Urban N: Simulation modeling of outcomes and cost effectiveness. Hematol Oncol Clin North Am 2000;14:925-938.
4. National Institute for Clinical Excellence: Guide to the Methods of Technology Appraisal (2004). http://www.nice.org.uk/pdf/TAP_Methods.pdf (last accessed 1 June 2005).
5. Academy of Managed Care Pharmacy: A format for submission of clinical and economic data in support of formulary consideration by health care systems in the United States (Version 2.0, 2002). http://www.amcp.org/data/nav_content/ formatv20%2Epdf (last accessed 1 June 2005).
6. Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz KM, Graham JD, Hammitt JK: Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001;4:348-361.
7. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, Matthews DR, Stratton IM, Holman RR; UK Prospective Diabetes Study (UKDPS) Group: A model to estimate the lifetime health outcomes of patients with type 2 diabetes mellitus: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-1759.
8. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA: The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl 1):S5-S26.
9. Brown JB, Russell A, Chan W, Pedula K, Aickin M: The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 2000;50(Suppl 3):S15-S46.
10. Brown JB, Palmer AJ, Bisgaard P, Chan W, Pedula K, Russell A: The Mt. Hood challenge: cross-testing two diabetes simulation models. Diabetes Res Clin Pract 2000;50(Suppl 3):S57-S64.
11. Coyle D, Lee KM, O'Brien BJ: The role of models within economic analysis: focus on type 2 diabetes mellitus. Pharmacoeconomics 2002;20(Suppl 1):11-19.
12. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, Maier W, Dong F, Manninen D, Zbrozek AS, Kotsanos J, Garfield SA, Harris MM: Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735-744.
13. American Diabetes Association Consensus Panel: Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-2265.
14. Thompson JR: Simulation-A Modeler's Approach. New York: John Wiley & Sons, Inc., 2000.
15. Klein R, Klein BE, Moss SE, DeMets DL, Kaufman I, Voss PS: Prevalence of diabetes mellitus in southern Wisconsin. Am J Epidemiol 1984;119:54-61.
16. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
17. The UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
18. Klein R, Moss S: A comparison of the study populations in the Diabetes Control and Complications Trial and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med 1995;155:745-754.
19. James F: RANLUX: a Fortran implementation of the high-quality pseudorandom number generator. Comput Phys Commun 1994;79:111-114.
20. James F: Erratum. RANLUX: A Fortran implementation of the high-quality pseudorandom number generator of Lüscher. Comput Phys Commun 1996;97:357.
21. Tull ES, Roseman JM: Diabetes in African Americans. In: Diabetes in America. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 1995:613-630.
22. Stern MP, Mitchell BD: Diabetes in Hispanic Americans. In: Diabetes in America. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 1995:631-660.
23. Fujimoto WY: Diabetes in Asian and Pacific Islander Americans. In: Diabetes in America. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 1995:661-682.
24. Vijan S, Hofer TP, Hayward RA: Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med 1997;127:788-795.
25. U.S. Renal Data System: USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 2004.
26. Koivisto VA, Stevens LK, Mattock M, Ebeling P, Muggeo M, Stephenson J, Idzior-Walus B: Cardiovascular disease and its risk factors in IDDM in Europe. The EURODIAB IDDM Complications Study Group. Diabetes Care 1996;19:689-697.
27. Lee CD, Folsom AR, Pankow JS, Brancati FL; Atherosclerosis Risk in Communities (ARIC) Study Investigators: Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation 2004;109:855-860.
28. Laing SP, Swerdlow AJ, Carpenter LM, Slater SD, Burden AC, Botha JL, Morris AD, Waugh NR, Gatling W, Gale EA, Patterson CC, Qiao Z, Keen H: Mortality from cerebrovascular disease in a cohort of 23,000 patients with insulin-treated diabetes. Stroke 2003;34:418-421.
29. Evans JMM, Wang J, Morris AD: Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 2002;324:939-942.
30. Colhoun HM, Bennett PH, Lu M, Keen H, Wang S-L, Stevens LK, Fuller JH; WHO Multinational Study Group: Risk factors for renal failure: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(Suppl 2):S46-S53.
31. The Diabetes Control and Complications Trial Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997;46:271-286.
32. The Diabetes Control and Complications (DCCT) Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995;47:271-286.
33. The Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995;122:561-568.
34. Klein R, Klein BE, Moss SE, Cruikshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIV. Ten year incidence and progression of diabetic retinopathy. Arch Ophthalmol 1994;112:1217-1228.
35. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995;102:7-16.
36. Moss SE, Klein R, Klein BE: Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994;101:1061-1070.
37. Klein R, Klein BE, Moss SE, Cruickshanks KJ, Brazy PC: The 10-year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care 1999;22:743-751.
38. Moss SE, Klein R, Klein BE: The 14-year incidence of lower-extremity amputations in a diabetic population. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 1999;22:951-959.
39. Moss SE, Klein R, Klein BE: The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 1992;152:610-616.
40. United Kingdom Prospective Diabetes Study Group: United Kingdom Prospective Diabetes Study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998;128:165-175.
41. World Health Organisation life tables for USA, UK, Germany, France, Spain. http://www3.who.int/whosis/life/life_tables/life_tables.cfm?path= evidence,life,life_tables&language=english (last accessed 16 June 2005).
42. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
43. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-419.
44. The UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713.
45. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801-1815.
46. Cruickshanks KJ, Moss SE, Klein R, Klein BE. Physical activity and proliferative retinopathy in people diagnosed with diabetes before age 30 yr. Diabetes Care 1992;15:1267-1272.
47. Klein BE, Klein R, McBride PE, Cruickshanks KJ, Palta M, Knudtson MD, Moss SE, Reinke JO: Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes. Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med 2004;164:1917-1924.
48. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-828.
49. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR; the UKPDS Study Group; The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 2001;101:671-679.
50. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, Holman RR; the UKPDS Study Group: UKPDS 60. Risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002;33:1776-1781.
51. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR: Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes. UKPDS 66. Diabetes Care 2004;27:201-207.
52. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial website. http://www.accordtrial.org/public/index.cfm (last accessed 22 July 2005).